ZURZUVAE

Growth

zuranolone

NDAORALCAPSULEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

GABA A Receptor Positive Modulators

Pharmacologic Class:

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

Clinical Trials (3)

NCT07398469N/ARecruiting

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

Started Dec 2025
200 enrolled
Postpartum Depression
NCT07047820N/ARecruiting

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

Started Jun 2025
200 enrolled
Depression, Postpartum
NCT05655507Phase 1Completed

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Started Apr 2023
19 enrolled
Major Depressive Disorder

Loss of Exclusivity

LOE Date
Aug 23, 2037
139 months away
Patent Expiry
Aug 23, 2037
Exclusivity Expiry
Oct 31, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10172871
Apr 17, 2034
U-2552
10342810
Apr 17, 2034
U-2552
9512165
Apr 17, 2034
SubstanceProduct
11236121
Aug 23, 2037
Substance
11884696
Aug 23, 2037
U-2552